# EdiGene

leading Chinese CRISPR gene editing company; ET-01 (base editing for beta-thalassaemia) in IND-enabling; CRISPR HSC programs under NMPA Fast Track.

Source: https://en.bioecon.ru/companies/edigene/
Updated: 2026-06-24

- Country: China

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $164M to $180M total funding raised | https://www.synbiobeta.com/read/edigene-raises-approximately-usd-62-million-in-series-b-plus-financing-and-expands-operation-locations-to-advance-and-scale-up-clinical-translation-of-gene-editing-technologies |
| Production site | cGMP manufacturing facility in Guangdong Province launched in 2018 | https://www.biospace.com/edigene-announces-ind-application-for-its-crispr-cas-9-gene-editing-hematopoietic-stem-cell-therapy-et-01-in-%CE%B2-thalassemia-accepted-for-review-by-china-national-medical-products-administration |
| Regulatory approval | NMPA IND approval for ET-01 in January 2021 | https://thalassaemia.org.cy/news/edigene-announces-approval-in-china-of-its-ind-application-for-crispr-cas-9-gene-editing-therapy-et-01-in-%CE%B2-thalassaemia/, https://www.biospace.com/edigene-announces-ind-application-for-its-crispr-cas-9-gene-editing-hematopoietic-stem-cell-therapy-et-01-in-%CE%B2-thalassemia-accepted-for-review-by-china-national-medical-products-administration, https://www.businesswire.com/news/home/20210118005210/en/EdiGene-Announces-Approval-of-its-IND-Application-for-its-CRISPRCas-9-Gene-editing-Hematopoietic-Stem-Cell-Therapy-ET-01-in--thalassemia-by-China-National-Medical-Products-Administration, https://www.lavfund.com/blog/edigene-announces-approval-of-its-ind-application-for-its-crispr-cas-9 |
| Headcount | approximately 46 employees as of July 2026 | https://www.caplight.com/company/edigene, https://www.datanyze.com/companies/edigene/399164728 |
| Revenue | Estimated annual revenue between $1.8M and $50M [medium confidence] | https://www.datanyze.com/companies/edigene/399164728 |

Independent sources: biospace.com, businesswire.com, caplight.com, datanyze.com, lavfund.com, synbiobeta.com, thalassaemia.org.cy

## Technologies

- [Base editing](https://en.bioecon.ru/technology/base-editing/)
- [Genome editing](https://en.bioecon.ru/technology/genome-editing/)
- [Personalized & regenerative medicine](https://en.bioecon.ru/technology/personalized-regenerative-medicine/)
- [Prime editing](https://en.bioecon.ru/technology/prime-editing/)